Zimmer Offers Update On Anticipated Device Tax Impact For 2013
This article was originally published in The Gray Sheet
The orthopedic device maker now forecasts the financial impact of the impending device excise tax in 2013 will be less for Zimmer than previously anticipated, since about half of it can be deferred by six months under the firm’s updated accounting plan.
You may also be interested in...
The continued rollout of the firm’s new Persona knee system will be critical to its 2013 earnings, Zimmer executives tell investors.
More DME competitive bidding planned. AdvaMed outlines strategic plan. Roche ends Illumina bid, for now.
The final health care reform device industry tax provision, while presenting a challenge, will be manageable by the sector at large, according to industry analysts